Building on the Strengths of DNA Medicine
Building on the strengths of our platform and a growing body of promising research, INOVIO is advancing the next generation of DNA medicines.
DNA-encoded Monoclonal Antibodies (DMAbs™)
Monoclonal antibodies (mAbs) are designed to enhance the immune system’s ability to regulate cell functions. Using our core DNA medicines platform, we’re pushing this technology further, encoding the DNA sequence for a specific mAb in a DNA plasmid. We deliver the plasmid directly into the body’s cells using our investigational CELLECTRA® device, enabling these cells to manufacture the mAbs in vivo – unlike conventional mAb technology that requires manufacture outside of the body. This offers some potential advantages over conventional mAbs, including a less frequent need for administration and lower manufacturing costs, that may enable greater access to mAb-based technology for more people and a wider range of diseases. Promising data from a Phase 1 proof-of-concept trial has been published in Nature Medicine, demonstrating the technology’s potential as a long-acting, scalable and tolerable alternative to traditional monoclonal antibody therapies.
DNA-Encoded Protein (DPROT) technology
A new approach to therapeutic protein replacement that builds on our DMAb research and aims to address some of the shortcomings of conventional therapeutic protein/enzyme replacement (which uses either repeated recombinant protein injections, infusions or viral based gene therapy). DPROT technology targets long-term protein expression within the body, making it a potentially transformative treatment modality for a range of diseases with significant unmet need. Promising preclinical data on Factor VIII production was presented at the World Federation of Hemophilia Global Forum in November 2025, demonstrating the groundbreaking potential of this next generation DNA medicine technology.
DNA-launched Nanoparticles (dLNPs)
This approach brings together the high immunogenicity benefits of nanoparticle technology-based vaccines with the in vivo protein production abilities of our core DNA medicines technology. Plasmids are designed to encode a specific antigen and self-assembling nanoparticle elements and can provide instructions to the body’s cells to make antigenic nanoparticles, which in turn stimulate the immune system to elicit robust binding and neutralizing antibody and T cell responses.
Innovative DNA Medicine Delivery Techniques
Our device engineering team is working on novel approaches to DNA medicine delivery that build on our decades of delivery device research.
